BREAST CANCER

The results of a recent randomized study showed anti-HER2 DC1 vaccination to be a safe and immunogenic treatment to induce tumor-specific T-cell responses in patients with HER2-positive breast cancer.

While mutations of the <em>BRCA</em> gene can increase a woman&rsquo;s chances of developing breast and ovarian cancers, the presence of the gene made no difference in survival for women aged 40 years or younger who were diagnosed with early-stage breast cancer.

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.

In a recent early-stage HER2-positive breast cancer trial, prophylactic treatment with the combination of loperamide and budesonide reduced the rate of grade 3 diarrhea associated with neratinib to 15%.

Sibylle Loibl, MD, PhD,&nbsp;co-chair of the German Breast Group and associate professor at the University of Frankfurt, discusses the most recent subanalysis of the GeparSepto trial in luminal, triple-negative, and HER2+ breast cancer.

Sibylle Loibl, MD, PhD, discusses the most recent subanalysis of the GeparSepto trial, how the drugs match up in terms of toxicities, and a separate set of data looking at patients with breast cancer who are also pregnant.

Julia White, MD, discusses the upcoming phase II trial, the toxicities associated with the treatment, and the potential for control of these metastases. According to White, the trial is still accruing its 143 patients.

Sara Tolaney, MD, MPH, associate clinical research director of Breast Oncology at the Dana-Farber Cancer Institute in Boston, discusses a clinical trial investigating pembrolizumab in combination with eribulin in triple-negative breast cancer.&nbsp;

Paul Kelly Marcom, MD, discusses the future landscape of HR-positive breast cancer, highlighting the influence of CDK4/6 inhibitors and targeted agent/endocrine therapy combinations.

Patients with breast cancer who received radiation therapy following a mastectomy reported increased complications and lower satisfaction, according to the results of a large, multicenter study.

Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses a phase II study of whole brain radiotherapy with concurrent lapatinib in patients with brain metasteses from HER2-positive breast cancer.

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women&rsquo;s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses a phase II trial looking at ONT-380 in HER2+ breast cancer.&nbsp;

The FDA has granted a priority review to a supplemental new drug application supporting the conversation of the accelerated approval of palbociclib to a full approval for use in combination with letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative metastatic breast cancer.

The FDA has approved the marketing of AeroForm, a new system for soft tissue expansion in 2-stage breast reconstruction following mastectomy, and in the treatment of underdeveloped breasts and soft tissue deformities.

The phase II HERMIONE trial was halted after the antibody-drug conjugate MM-302 combined with trastuzumab (Herceptin) failed to improve progression-free survival (PFS) versus chemotherapy plus trastuzumab in patents with HER2-positive metastatic breast cancer who had previously received trastuzumab, pertuzumab (Perjeta), and ado-trastuzumab emtansine (T-DM1, Kadcyla).

According to results presented during the 2016 San Antonio Breast Cancer Symposium,&nbsp;neoadjuvant combination of CDK4/6 inhibitor abemaciclib plus anastrazole may represent a novel therapeutic option for patients with hormone receptor (HR)-positive, HER2-negative early breast cancer.

The 2017 Miami Breast Cancer Conference, to be held March 9 to 12 at the Fontainebleau Miami Beach, welcomes an expanded group of program chairs, and a newly established curriculum committee made up of a multidisciplinary group of breast cancer specialists.

Patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer, and visceral metastases obtained a significant benefit from treatment with the CDK4/6 inhibitor ribociclib (LEE011) combined with letrozole, a subgroup analysis of the randomized MONALEESA-2 trial showed.

The American Association for Cancer Research (AACR) recently recognized 2 renowned researchers for their work in breast cancer during the 2016 San Antonio Breast Cancer Symposium (SABCS).

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the dilemma of managing a patient who has residual disease after receiving neoadjuvant therapy.

BRCA1 methylation or silencing does not predict for a better response to carboplatin over docetaxel in women with advanced triple-negative or BRCA1/2 breast cancer, according to results from a pre-planned biological analysis of the phase III TNT trial.

Continuous low-dose ribociclib shows preliminary activity, and has an acceptable safety profile as an alternative to intermittent ribociclib dosing when combined with fulvestrant in the treatment of postmenopausal women with hormone receptor-positive, <em>HER2</em>-negative advanced breast cancer.

The combination of pembrolizumab and eribulin demonstrated a 33.3% objective response rate for patients with metastatic triple-negative breast cancer who received 0 to 2 prior lines of therapy.

Pembrolizumab (Keytruda) continued to show a consistent durable benefit with an additional year of follow-up for heavily pretreated patients with recurrent PD-L1-positive metastatic triple-negative breast cancer.

Women who are experiencing symptoms of menopause are less likely to adhere to treatment, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.

The artificial intelligence computer program Watson for Oncology (WFO) achieved a high degree of concordance with tumor board recommendations in a double-blinded validation study in Bengaluru, India, according to results presented at the 2016 San Antonio Breast Cancer Symposium (SABCS).

There has been renewed interest in eribulin mesylate (Halaven) following its FDA approval for advanced or unresectable liposarcoma and with the introduction of a growing body of preclinical work suggesting the agent has a novel anti&ndash;mesenchymal mechanism of action.

Recent promising findings with the neoadjuvant combination of the CDK4/6 inhibitor abemaciclib with anastrozole could lead to a novel therapeutic option for patients with hormone receptor (HR)&ndash;positive, HER2-negative early breast cancer.

Hyo Sook Han, MD, medical oncologist, Moffitt Cancer Center, discusses results of the phase II BROCADE trial, which evaluated the combination of the PARP inhibitor veliparib with carboplatin/paclitaxel in patients with <em>BRCA</em>-positive breast cancer.

William J. Gradishar, MD, deputy director of the Robert H. Lurie Comprehensive Cancer Center at Northwestern University Feinberg School of Medicine, discusses the takeaways from the TransATAC trial, which was a comprehensive comparison of prognostic signatures in breast cancer.